309 related articles for article (PubMed ID: 23808883)
1. The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies.
Collin M; Ehlers M
Exp Dermatol; 2013 Aug; 22(8):511-4. PubMed ID: 23808883
[TBL] [Abstract][Full Text] [Related]
2. Sialylated Autoantigen-Reactive IgG Antibodies Attenuate Disease Development in Autoimmune Mouse Models of Lupus Nephritis and Rheumatoid Arthritis.
Bartsch YC; Rahmöller J; Mertes MMM; Eiglmeier S; Lorenz FKM; Stoehr AD; Braumann D; Lorenz AK; Winkler A; Lilienthal GM; Petry J; Hobusch J; Steinhaus M; Hess C; Holecska V; Schoen CT; Oefner CM; Leliavski A; Blanchard V; Ehlers M
Front Immunol; 2018; 9():1183. PubMed ID: 29928274
[TBL] [Abstract][Full Text] [Related]
3. T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies.
Hess C; Winkler A; Lorenz AK; Holecska V; Blanchard V; Eiglmeier S; Schoen AL; Bitterling J; Stoehr AD; Petzold D; Schommartz T; Mertes MM; Schoen CT; Tiburzy B; Herrmann A; Köhl J; Manz RA; Madaio MP; Berger M; Wardemann H; Ehlers M
J Clin Invest; 2013 Sep; 123(9):3788-96. PubMed ID: 23979161
[TBL] [Abstract][Full Text] [Related]
4. Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs.
Oefner CM; Winkler A; Hess C; Lorenz AK; Holecska V; Huxdorf M; Schommartz T; Petzold D; Bitterling J; Schoen AL; Stoehr AD; Vu Van D; Darcan-Nikolaisen Y; Blanchard V; Schmudde I; Laumonnier Y; Ströver HA; Hegazy AN; Eiglmeier S; Schoen CT; Mertes MM; Loddenkemper C; Löhning M; König P; Petersen A; Luger EO; Collin M; Köhl J; Hutloff A; Hamelmann E; Berger M; Wardemann H; Ehlers M
J Allergy Clin Immunol; 2012 Jun; 129(6):1647-55.e13. PubMed ID: 22502800
[TBL] [Abstract][Full Text] [Related]
5. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.
Fokkink WJ; Selman MH; Dortland JR; Durmuş B; Kuitwaard K; Huizinga R; van Rijs W; Tio-Gillen AP; van Doorn PA; Deelder AM; Wuhrer M; Jacobs BC
J Proteome Res; 2014 Mar; 13(3):1722-30. PubMed ID: 24533874
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.
Kaneko Y; Nimmerjahn F; Ravetch JV
Science; 2006 Aug; 313(5787):670-3. PubMed ID: 16888140
[TBL] [Abstract][Full Text] [Related]
7. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins.
Ahmed AA; Giddens J; Pincetic A; Lomino JV; Ravetch JV; Wang LX; Bjorkman PJ
J Mol Biol; 2014 Sep; 426(18):3166-3179. PubMed ID: 25036289
[TBL] [Abstract][Full Text] [Related]
8. Novel roles for the IgG Fc glycan.
Anthony RM; Wermeling F; Ravetch JV
Ann N Y Acad Sci; 2012 Apr; 1253():170-80. PubMed ID: 22288459
[TBL] [Abstract][Full Text] [Related]
9. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity.
Nimmerjahn F; Anthony RM; Ravetch JV
Proc Natl Acad Sci U S A; 2007 May; 104(20):8433-7. PubMed ID: 17485663
[TBL] [Abstract][Full Text] [Related]
10. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs.
Anthony RM; Ravetch JV
J Clin Immunol; 2010 May; 30 Suppl 1():S9-14. PubMed ID: 20480216
[TBL] [Abstract][Full Text] [Related]
11. [Glycosylation-dependent effector function of IgG antibodies].
Ehlers M
Z Rheumatol; 2012 Nov; 71(9):798-800. PubMed ID: 23138557
[TBL] [Abstract][Full Text] [Related]
12. Glycan analysis of monoclonal antibodies secreted in deposition disorders indicates that subsets of plasma cells differentially process IgG glycans.
Omtvedt LA; Royle L; Husby G; Sletten K; Radcliffe CM; Harvey DJ; Dwek RA; Rudd PM
Arthritis Rheum; 2006 Nov; 54(11):3433-40. PubMed ID: 17075835
[TBL] [Abstract][Full Text] [Related]
13. The antiinflammatory activity of IgG: the intravenous IgG paradox.
Nimmerjahn F; Ravetch JV
J Exp Med; 2007 Jan; 204(1):11-5. PubMed ID: 17227911
[TBL] [Abstract][Full Text] [Related]
14. Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy.
Stümer J; Biermann MHC; Knopf J; Magorivska I; Kastbom A; Svärd A; Janko C; Bilyy R; Schett G; Sjöwall C; Herrmann M; Muñoz LE
Clin Exp Immunol; 2017 Sep; 189(3):372-382. PubMed ID: 28509333
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the glycosylation of in vitro generated polyclonal human IgG and therapeutic immunoglobulins.
Ritamo I; Cloutier M; Valmu L; Néron S; Räbinä J
Mol Immunol; 2014 Feb; 57(2):255-62. PubMed ID: 24184880
[TBL] [Abstract][Full Text] [Related]
16. Terminal sugars of Fc glycans influence antibody effector functions of IgGs.
Raju TS
Curr Opin Immunol; 2008 Aug; 20(4):471-8. PubMed ID: 18606225
[TBL] [Abstract][Full Text] [Related]
17. Glycosylation of random IgG distinguishes seropositive and seronegative rheumatoid arthritis.
Magorivska I; Döncző B; Dumych T; Karmash A; Boichuk M; Hychka K; Mihalj M; Szabó M; Csánky E; Rech J; Guttman A; Vari SG; Bilyy R
Autoimmunity; 2018 May; 51(3):111-117. PubMed ID: 29733234
[TBL] [Abstract][Full Text] [Related]
18. Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain.
Yu X; Vasiljevic S; Mitchell DA; Crispin M; Scanlan CN
J Mol Biol; 2013 Apr; 425(8):1253-8. PubMed ID: 23416198
[TBL] [Abstract][Full Text] [Related]
19. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?
Siragam V; Brinc D; Crow AR; Song S; Freedman J; Lazarus AH
J Clin Invest; 2005 Jan; 115(1):155-60. PubMed ID: 15630455
[TBL] [Abstract][Full Text] [Related]
20. IgG Glyco-Engineering to Improve IVIg Potency.
Bruggeman CW; Dekkers G; Visser R; Goes NWM; van den Berg TK; Rispens T; Vidarsson G; Kuijpers TW
Front Immunol; 2018; 9():2442. PubMed ID: 30405631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
